Comprehensive Pan-Cancer Analysis of the Prognostic and Immunological Roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C Axis

Growing evidence has demonstrated that UBE2C plays a critical role in cancer progression, but there is no study focusing on the prognosis, upstream regulation mechanism, and immunological roles of UBE2C across diverse tumor types. In this study, we found that UBE2C was elevated in this human pan-cancer analysis, and high expression of UBE2C was correlated with poor prognosis. In addition, UBE2C expression was markedly associated with tumor mutation burden (TMB), microsatellite instability (MSI), immune cell infiltration, and diverse drug sensitivities. Finally, we showed that the METTL3/SNHG1/miRNA-140-3p axis could potentially regulate UBE2C expression. N(6)-Methyladenosine (m6A) modifications improved the stability of methylated SNHG1 transcripts by decreasing the rate of RNA degradation, which lead to upregulation of SNHG1 in non-small cell lung cancer (NSCLC). In vitro functional experiments showed that SNHG1, as a competing endogenous RNA, sponges miR-140-3p to increase UBE2C expression in NSCLC cell lines. Our study elucidates the clinical importance and regulatory mechanism of the METTL3/SNHG1/miRNA-140-3p/UBE2C axis in NSCLC and provides a prognostic indicator, as well as a promising therapeutic target for patients with NSCLC.

[1]  Yong Duan,et al.  miR-133b targets NCAPH to promote β-catenin degradation and reduce cancer stem cell maintenance in non-small cell lung cancer , 2021, Signal Transduction and Targeted Therapy.

[2]  M. Zou,et al.  miR-17-5p accelerates cervical cancer cells migration and invasion via the TIMP2/MMPs signaling cascade , 2021, Cytotechnology.

[3]  W. Jin,et al.  MiR-513b-5p represses autophagy during the malignant progression of hepatocellular carcinoma by targeting PIK3R3 , 2021, Aging.

[4]  A. Addeo,et al.  TMB or not TMB as a biomarker: That is the question. , 2021, Critical reviews in oncology/hematology.

[5]  Jie Liu,et al.  Silencing of hsa_circ_0009035 Suppresses Cervical Cancer Progression and Enhances Radiosensitivity through MicroRNA 889-3p-Dependent Regulation of HOXB7 , 2021, Molecular and Cellular Biology.

[6]  Xiaohong Wang,et al.  m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis , 2021, Journal of Hematology & Oncology.

[7]  A. Chiang,et al.  UBE2C Drives Human Cervical Cancer Progression and Is Positively Modulated by mTOR , 2020, Biomolecules.

[8]  J. Huse,et al.  YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. , 2020, Cancer cell.

[9]  L. Ger,et al.  UBE2C is a Potential Biomarker for Tumorigenesis and Prognosis in Tongue Squamous Cell Carcinoma , 2020, Diagnostics.

[10]  Yangqiu Li,et al.  Roles of METTL3 in cancer: mechanisms and therapeutic targeting , 2020, Journal of Hematology & Oncology.

[11]  Zhon-Yin Zhang,et al.  Long non‐coding RNA SCARNA2 induces cutaneous squamous cell carcinoma progression via modulating miR‐342‐3p expression , 2020, The journal of gene medicine.

[12]  Chang Hoon Shin,et al.  MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer , 2020, British Journal of Cancer.

[13]  T. Kouzarides,et al.  Role of RNA modifications in cancer , 2020, Nature Reviews Cancer.

[14]  Ningning Yang,et al.  lncRNA SNHG11 promotes lung cancer cell proliferation and migration via activation of Wnt/β‐catenin signaling pathway , 2020, Journal of cellular physiology.

[15]  Yanhua Kang,et al.  Long Noncoding RNA XIST Contributes to Cervical Cancer Development Through Targeting miR-889-3p/SIX1 Axis. , 2020, Cancer biotherapy & radiopharmaceuticals.

[16]  P. Wei,et al.  MiR-140-3p Ameliorates the Progression of Osteoarthritis via Targeting CXCR4. , 2020, Biological & pharmaceutical bulletin.

[17]  X. Gou,et al.  Long noncoding RNA TUG1 regulates prostate cancer cell proliferation, invasion and migration via the Nrf2 signaling axis. , 2020, Pathology, research and practice.

[18]  Xuehao Wang,et al.  M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma , 2020, Journal of Hematology & Oncology.

[19]  Haiyan Ye,et al.  Up-regulation of circ_LARP4 suppresses cell proliferation and migration in ovarian cancer by regulating miR-513b-5p/LARP4 axis , 2020, Cancer Cell International.

[20]  Xiuling Zhi,et al.  Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1. , 2019, Biochemical and biophysical research communications.

[21]  Shen Hu,et al.  UBE2C promotes the progression of head and neck squamous cell carcinoma. , 2019, Biochemical and biophysical research communications.

[22]  Xiaomei Li,et al.  LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non‐small cell lung cancer cells via the miR‐361‐3p/FRAT1 axis , 2019, Thoracic cancer.

[23]  Jia Liu,et al.  LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer , 2019, Molecular Cancer.

[24]  Li-xiu Liu,et al.  MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C/ZEB1/2 Signal Axis , 2019, Digestive Diseases and Sciences.

[25]  Hongbo Wang,et al.  UBE2C Is Upregulated by Estrogen and Promotes Epithelial–Mesenchymal Transition via p53 in Endometrial Cancer , 2019, Molecular Cancer Research.

[26]  Q. Ding,et al.  Anticancer effect of icaritin on prostate cancer via regulating miR‐381‐3p and its target gene UBE2C , 2019, Cancer medicine.

[27]  Beibei Ru,et al.  TISIDB: an integrated repository portal for tumor-immune system interactions , 2019, Bioinform..

[28]  Wei Wu,et al.  Combined elevation of AURKB and UBE2C predicts severe outcomes and therapy resistance in glioma. , 2019, Pathology, research and practice.

[29]  F. Shao,et al.  Long non-coding RNA TUG1-mediated down-regulation of KLF4 contributes to metastasis and the epithelial-to-mesenchymal transition of colorectal cancer by miR-153-1 , 2019, Cancer management and research.

[30]  Kaiyu Qian,et al.  Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma , 2019, Aging.

[31]  D. Lin,et al.  METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma , 2019, Molecular Cancer.

[32]  Mengquan Li,et al.  SNHG1 contributes to proliferation and invasion by regulating miR-382 in breast cancer , 2019, Cancer management and research.

[33]  T. Li,et al.  LncRNA TUG1 aggravates the progression of prostate cancer and predicts the poor prognosis. , 2019, European review for medical and pharmacological sciences.

[34]  Jun Zhao,et al.  UBE2C overexpression in melanoma and its essential role in G2/M transition , 2019, Journal of Cancer.

[35]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[36]  H. Shan,et al.  m6A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1 , 2019, Molecular Cancer.

[37]  Y. Xiong,et al.  UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells , 2019, Bioscience reports.

[38]  Xiaohong Wang,et al.  UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC , 2019, Theranostics.

[39]  N. Brockdorff,et al.  m6A modification of non-coding RNA and the control of mammalian gene expression. , 2019, Biochimica et biophysica acta. Gene regulatory mechanisms.

[40]  Aiying Zhang,et al.  Identification of key genes and pathways in hepatocellular carcinoma , 2019, Medicine.

[41]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[42]  O. Rando,et al.  Transgenerational Epigenetic Inheritance. , 2018, Annual review of genetics.

[43]  Min Liu,et al.  The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA‐342‐3p target sequence , 2018, Journal of cellular physiology.

[44]  Wei Liu,et al.  CancerSEA: a cancer single-cell state atlas , 2018, Nucleic Acids Res..

[45]  Yu-qin Pan,et al.  The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p , 2018, Molecular Cancer.

[46]  Yan Chen,et al.  LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells , 2018, Medicine.

[47]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[48]  Zhen Cao,et al.  The lncLocator: a subcellular localization predictor for long non‐coding RNAs based on a stacked ensemble classifier , 2018, Bioinform..

[49]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[50]  G. Ma,et al.  Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. , 2018, European review for medical and pharmacological sciences.

[51]  Yanyan Li,et al.  Long noncoding RNA SNHG1 promotes non‐small cell lung cancer progression by up‐regulating MTDH via sponging miR‐145–5p , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  Zuozhang Yang,et al.  GRK5 functions as an oncogenic factor in non-small-cell lung cancer , 2018, Cell Death & Disease.

[53]  Yuan-yuan Liu,et al.  LncRNA SNHG1 enhances cell proliferation, migration, and invasion in cervical cancer. , 2018, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[54]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[55]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[56]  E. Sherwood,et al.  Targeting Immune Cell Checkpoints during Sepsis , 2017, International journal of molecular sciences.

[57]  F. Kühnel,et al.  CD4 and CD8 T lymphocyte interplay in controlling tumor growth , 2017, Cellular and Molecular Life Sciences.

[58]  Gui-Shuan Wang,et al.  Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells. , 2017, Gene.

[59]  W. Jiang,et al.  Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer. , 2017, Anticancer research.

[60]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[61]  Yan Gao,et al.  LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145 , 2017, Acta biochimica et biophysica Sinica.

[62]  Ge Gao,et al.  CPC2: a fast and accurate coding potential calculator based on sequence intrinsic features , 2017, Nucleic Acids Res..

[63]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[64]  Zhike Lu,et al.  m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. , 2017, Cancer cell.

[65]  S. Wen,et al.  Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan–Meier plotter , 2017, PloS one.

[66]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.

[67]  賢治 高橋,et al.  膵癌とlong non-coding RNA , 2016 .

[68]  Yan Fu,et al.  MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling , 2015, Journal of Biological Research-Thessaloniki.

[69]  Jun Ma,et al.  Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway , 2015, Medical Oncology.

[70]  Hui Zhou,et al.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data , 2013, Nucleic Acids Res..

[71]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[72]  A. Jouvet,et al.  Molecular characterization of central neurocytomas: Potential markers for tumor typing and progression , 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.

[73]  Qun Chen,et al.  Prognostic significance of serum miR-17-5p in lung cancer , 2013, Medical Oncology.

[74]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[75]  Hui Zhang,et al.  Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker , 2012, Tumor Biology.

[76]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[77]  T. Strutt,et al.  Expanding roles for CD4+ T cells in immunity to viruses , 2012, Nature Reviews Immunology.

[78]  M. Otsuka,et al.  MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators. , 2011, Biochemical and biophysical research communications.

[79]  S. Roychoudhury,et al.  Spindle Assembly Checkpoint Protein Cdc20 Transcriptionally Activates Expression of Ubiquitin Carrier Protein UbcH10* , 2011, The Journal of Biological Chemistry.

[80]  Thangarajan Rajkumar,et al.  Identification and validation of genes involved in cervical tumourigenesis , 2011, BMC Cancer.

[81]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[82]  Per Karlsson,et al.  Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma , 2010, Clinical Cancer Research.

[83]  C. Boland,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[84]  Xian-xi Liu,et al.  Association of clinicopathological features with UbcH10 expression in colorectal cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[85]  J. V. van Deursen,et al.  Overexpression of the E2 ubiquitin–conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation , 2010, The Journal of cell biology.

[86]  R. Lotan,et al.  Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System , 2009, Cancer Prevention Research.

[87]  K. Nakai,et al.  PrognoScan: a new database for meta-analysis of the prognostic value of genes , 2009, BMC Medical Genomics.

[88]  A. Fusco,et al.  Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors. , 2008, Clinical neuropathology.

[89]  K. Mimori,et al.  Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin‐conjugating enzyme E2C gene expression , 2007, International journal of cancer.

[90]  Viji M. Draviam,et al.  Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities , 2007, Nature.

[91]  M. Guida,et al.  UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas , 2007, Oncogene.

[92]  D. Beer,et al.  Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. , 2006, Neoplasia.

[93]  Marc W. Kirschner,et al.  The Processivity of Multiubiquitination by the APC Determines the Order of Substrate Degradation , 2006, Cell.

[94]  Akira Nakagawara,et al.  UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. , 2003, Cancer research.

[95]  A. Admon,et al.  E2-C, a cyclin-selective ubiquitin carrier protein required for the destruction of mitotic cyclins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[96]  J. Yuan,et al.  LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway. , 2018, European review for medical and pharmacological sciences.